Diagnósticos da América (DASA3) investor relations material

Executive summary

• Completed a major joint venture with Amil, forming Regia Medicas/Rede Américas, one of Brazil's largest hospital groups, and refocused on diagnostics as the main business.

• New leadership and organizational structure implemented, emphasizing operational excellence, productivity, and digital transformation.

• Significant progress in digital transformation, improving patient and physician experience.

• Operational efficiency improved through standardization, logistics integration, and discontinuation of underperforming units.

• Strategic moves have positively impacted operations and capital structure, with the lowest leverage since 2021.

Financial highlights

• Consolidated gross revenue for 2Q25 was R$2.7 billion, down 37% year-over-year due to deconsolidation of JV hospitals; Diagnostics revenue grew 6% while Hospitals and Oncology Northeast declined 3%.

• Gross margin expanded by 0.9 p.p. to 29.7%; consolidated EBITDA rose 10% to R$738 million, with EBITDA margin up to 29.9%.

• Net debt reduced by BRL 3.4 billion, ending the quarter at BRL 7.3 billion; leverage dropped to 2.82x net debt/EBITDA, lowest since 2021.

• Positive cash generation of BRL 44 million; cash cycle reduced by six days sequentially.

• Net result was a loss of R$173 million, impacted by non-recurring items and income tax effects.

Outlook and guidance

• Continued focus on diagnostics as the core business, operational efficiency, and digital transformation initiatives.

• Ongoing review of processes and cost structure, with further improvements expected in SG&A and margins.

• Integration of Regia Medicas/Rede Américas expected to yield further synergies and productivity gains.

• Prioritization of high-return investment projects and maintenance of strategic assets.